This is a pilot trial testing the safety and feasibility of using PSMA-PET and mpMRI to optimize radiotherapy targets for patients with low-risk or intermediate-risk prostate cancer.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Michael Repka
Radiation Oncology - Chapel Hill
Clinical or Medical
Interventional
Cancer (Prostate)
19-1123
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
